| Chronic Lymphocytic Leukemia
Venclexta vs Bendeka
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Venclexta vs Bendeka with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBendeka has a higher rate of injection site reactions vs Venclexta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bendeka but not Venclexta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Venclexta
Bendeka
At A Glance
Oral
Once daily
BCL-2 inhibitor
IV infusion
Every 3-4 weeks
Alkylating agent
Indications
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Leukemia, Myelocytic, Acute
- Chronic Lymphocytic Leukemia
- Indolent B-Cell Non-Hodgkin Lymphoma
Dosing
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 5-week ramp-up starting at 20 mg, increasing to 400 mg orally once daily; used as monotherapy or in combination with acalabrutinib, obinutuzumab, or rituximab.
Leukemia, Myelocytic, Acute 3- or 4-day ramp-up to 400 mg orally once daily in combination with azacitidine or decitabine, or 600 mg orally once daily in combination with low-dose cytarabine, each in 28-day cycles.
Chronic Lymphocytic Leukemia 100 mg/m2 IV over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
Indolent B-Cell Non-Hodgkin Lymphoma 120 mg/m2 IV over 10 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.
Contraindications
- Concomitant use with strong CYP3A inhibitors at initiation and during the ramp-up phase in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma due to increased risk of tumor lysis syndrome
- Known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol
Adverse Reactions
Most common (>=20%) in CLL/SLL Neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, edema
Most common (>=30%) in AML Nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, hemorrhage, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, hypotension
Serious Tumor lysis syndrome, febrile neutropenia, pneumonia, sepsis, hemorrhage
Most common (>=30%) Nausea, fatigue, vomiting, diarrhea, pyrexia
Serious Febrile neutropenia, pneumonia, acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, myelodysplastic syndrome
Postmarketing Pancytopenia, atrial fibrillation, congestive heart failure, myocardial infarction, anaphylaxis, progressive multifocal leukoencephalopathy, nephrogenic diabetes insipidus, pneumonitis, DRESS, non-melanoma skin cancer, Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
BCL-2 inhibitor; venetoclax is a selective, orally bioavailable small-molecule that restores apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM and triggering mitochondrial outer membrane permeabilization and activation of caspases.
Bendamustine is a bifunctional mechlorethamine derivative containing a benzimidazole ring that forms electrophilic alkyl groups, which create covalent interstrand DNA crosslinks leading to cell death via multiple pathways; it is active against both quiescent and dividing cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Venclexta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Bendeka
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Venclexta
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Bendeka
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Venclexta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Bendeka
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Venclexta.
No savings programs available for Bendeka.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VenclextaView full Venclexta profile
BendekaView full Bendeka profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.